Abstract
As the human race evolves, numerous diseases have dominated humans, causing scientists to encounter myriad challenges with formulations. To rectify these issues, Nanoparticle (10-9 m) formulation approach or nanotechnology has been developed. Since nanoparticles have legion benefits, encompassing better bioavailability, target-specific, confined, accurate dose delivery, and increased surface area, are pertinent for effective treatment. Toxicity, inflammation, limited penetrating ability, accumulation, and aggregation are some of the downsides of nanoparticles. Picoscale along with nanoparticle technology in drug delivery, will enhance the permeability and myriad factors. Also, picometer (10-12 m) and futuristic femtometer (10-15 m) particles will allow scientists to deal with atomic and subatomic levels in some cases and improve the properties of nanotechnology in others. Herein, picotechnology, formulation, synthesis, and some unique properties concluding with femtotechnology have been addressed.
Keywords: Nanoparticle, nanotechnology, bioavailability, picometer, picotechnology, femtometer, femtotechnology.
[http://dx.doi.org/10.1016/j.biopha.2019.109484] [PMID: 31568989]
[http://dx.doi.org/10.5958/0975-4377.2018.00007.1]
[http://dx.doi.org/10.1016/B978-0-12-813477-1.00009-8]
[http://dx.doi.org/10.1007/s11356-019-06554-4] [PMID: 31832939]
[http://dx.doi.org/10.1007/978-3-319-46835-8_1]
[http://dx.doi.org/10.1039/C4TB00015C] [PMID: 32261580]
[http://dx.doi.org/10.1007/s10544-008-9264-6] [PMID: 19096767]
[http://dx.doi.org/10.1038/s41565-022-01111-6] [PMID: 35437320]
[http://dx.doi.org/10.1038/npre.2010.4525.1]
[http://dx.doi.org/10.1016/j.snb.2005.03.043]
[PMID: 24872699]
[http://dx.doi.org/10.1093/toxsci/kfg243] [PMID: 14514958]
[PMID: 22395840]
[http://dx.doi.org/10.11648/j.nano.20170506.13]
[http://dx.doi.org/10.1007/978-94-007-1100-6_12]
[http://dx.doi.org/10.1007/978-0-387-31122-7_4]
[http://dx.doi.org/10.1007/978-0-387-31122-7_1]
[http://dx.doi.org/10.3892/ijo.2013.1774] [PMID: 23338860]
[http://dx.doi.org/10.14447/jnmes.v24i4.a10]
[http://dx.doi.org/10.3892/mmr.2014.2953] [PMID: 25405328]
[http://dx.doi.org/10.1007/s11947-011-0731-3]
[http://dx.doi.org/10.1016/j.mehy.2020.109917] [PMID: 32505072]
[PMID: 33164589]
[http://dx.doi.org/10.1016/j.jare.2020.03.005] [PMID: 32257431]
[http://dx.doi.org/10.1016/j.ifset.2011.05.001]
[http://dx.doi.org/10.1016/j.ygyno.2016.02.001] [PMID: 26851601]
[http://dx.doi.org/10.1166/qm.2012.1015]
[http://dx.doi.org/10.1001/jamadermatol.2018.2671] [PMID: 30208473]
[http://dx.doi.org/10.1136/aim.26.3.133] [PMID: 18818558]
[http://dx.doi.org/10.4172/2090-4967.1000139]
[http://dx.doi.org/10.3844/ajeassp.2009.501.514]